Everything below concerns melanotan-2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Sinokrot Holding is the largest family-owned business group in Palestine, established in 1982. It is based in Ramallah, operating in 20,000 m2 of buildings with 350 employees. The company sells from more than 4,000 outlets. The chairman, Mazen Sinokrot, who was a Minister of National Economy until March 2006, as well as Chairman of the Board for the Palestine Standards Institute, Palestine Investment and Promotion Agency, and Palestine Industrial Zones and Free Zones Authority.
== History == The discovery of nanocellulosic materials can be traced back to late 1940s studies on the hydrolysis of cellulose fibers. Eventually it was noticed that cellulose hydrolysis seemed to occur preferentially at some disordered intercrystalline portions of the fibers. This led to the obtention of colloidally stable and highly crystalline nanorods particles. These particles were first referred to as micelles, before being given multiple names including cellulose nanocrystals (CNCs), nanocrystalline cellulose (NCC), or cellulose (nano)whiskers, though this last term is less used today. Later studies by O. A. Battista showed that in milder hydrolysis conditions, the crystalline nanorods stay aggregated as micron size objects. This material was later referred to as microcrystalline cellulose (MCC) and commercialised under the name Avicel by FMC Corporation.
== Types == Since the definition of well-being spans several dimensions, researchers have proposed various frameworks to capture its different forms. Types of well-being can be categorized by how they are measured, to whom they apply, and which domain of life they affect. Some researchers limit their inquiry to one specific type, while others investigate the interrelations among them.
Sources: en.wikipedia.org
==== "Depression Baby" ==== During the 1930s, the North American Car Company produced a one-of-a-kind, four-wheeled ice-bunker reefer intended to serve the needs of specialized shippers who did not generate enough product to fill a full-sized refrigerator car. NADX #10000 was a 22-foot (6.71 m)-long, all-steel car that resembled the forty-and-eights used in Europe during World War I. The prototype weighed 13.5 short tons (12.2 t; 12.1 long tons) and was outfitted with a 1,500 lb (680 kg) ice bunker at each end. The car was leased to Hormel and saw service between Chicago, Illinois and the southern United States. The concept failed to gain acceptance with eastern railroads, and no additional units were built.
As there are more customers using cards and mobile apps, Starbucks has decided to reduce the amount of stores that use cash. However, for the elderlies and foreigners, they do accept cash in rare occasions. This is not only to apply the newest technology to the stores, but to apply the change of lifestyle, making it convenient for both the customers and partners. Starbucks Korea said October 16, 2024. it has partnered with the country's leading retail lender KB Kookmin Bank to introduce account-based settlement services for its customers in the first quarter of next year. Starbucks Korea announced on the 28th Oct. that it will increase the prices of 11 tall (355ml) iced beverages on its menu from the 1st of next month. The price increase will include two blended drinks, six frappuccinos, one physio, and two refreshers, each of which will increase by 200 won.
== History == In the early 1960s, Dr. Arnold Kadish, a physician working at Loma Linda University, developed a closed-loop device for blood glucose control using a double-lumen autoanalyzer to measure blood glucose linked to an intravenous insulin infusion pump. Although it worked, the prototype was considered so bulky, worn as a backpack, and complicated, that it was never commercialized. In 1976, the first commercialized insulin pump was created and was named the Biostator. The pump was a 60 kg bedside device. It also had the capability of monitoring blood glucose levels, so this also doubles as the first continuous glucose monitor. Between 1978 and 1988, Robert Channon, working with Guy's Hospital and the Bristol Royal Infirmary, developed a series of miniature insulin infusion pumps. Today, insulin pumps are so small that they can fit in a pocket or a purse. In the late 1970s and early 1980s, Sandia National Laboratories and the University of New Mexico School of Medicine developed a remotely programmable implantable insulin infusion system that was tested in animals and implanted in human patients beginning in 1981. In 1984, an Infusaid implantable infusion device was used to treat a 22-year-old patient successfully. The insulin pump was first endorsed in the United Kingdom in 2003 by the National Institute for Health and Care Excellence (NICE).
Sources: en.wikipedia.org
Faculty member Isabelle Rapin has been described as a "founding mother of autism" and popularized the term "autism spectrum disorder". In 2019, researchers at Einstein mapped the entire nervous system of Caenorhabditis elegans, a classic model organism. Other work includes the discovery of the Tc1/mariner transposon superfamily and the invention of single molecule mRNA fluorescent in situ hybridization.
Gentle, non-irritating cleansers and moisturizers are often used alongside medicated treatments to maintain the skin barrier. The condition is common in infants within the first three months of age and adults aged 30 to 70 years. It is more common in males, African Americans, the immunocompromised (such as those with HIV), and those with Parkinson's disease.
=== Purines === Phosphoribosyltransferases add activated ribose-5-phosphate (Phosphoribosyl pyrophosphate, PRPP) to bases, creating nucleoside monophosphates. There are two types of phosphoribosyltransferases: adenine phosphoribosyltransferase (APRT) and hypoxanthine-guanine phosphoribosyltransferase (HGPRT). HGPRT is an important enzyme in Purine pathway metabolism and its deficiency is implicated in Lesch–Nyhan syndrome.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.